Biocon Launches New Drug in UK for Diabetes and Obesity Management
02 Mar 2025
Biotech company Biocon has introduced its drug for the management of diabetes and obesity in the United Kingdom, its first major milestone as a player in the international pharma market. Liraglutide, an GLP-1 peptide, will be traded as Liraglutide Biocon for diabetes and Biolide for long-term weight management, Biocon said...
Read More
